As the US biologics market crosses the $190 billion mark in 2024 and accelerates toward $400 billion by 2035, one trend is clear: biologics are no longer optional, they're essential.

Nowhere is this shift more visible than in spine surgery, where biologics are increasingly being used by interventional pain physicians and orthopedic surgeons to improve outcomes, reduce complications, and support outpatient surgical models.

Spine Surgeons and Pain Physicians Are Driving Biologic Adoption

In today’s spine care environment, procedural success is about more than hardware. Whether in SI joint fusion, facet fusion, or lumbar interbody procedures, physicians are turning to biologics to:

• Enhance fusion rates in high-risk patients

• Reduce reliance on autografts and iliac crest harvesting

• Support healing in minimally invasive approaches, especially in ASCs

As interventional pain physicians expand their procedural toolkit beyond injections into structural procedures, and orthopedic surgeons focus on reducing surgical morbidity, biologics are becoming a common thread in both practices.

A Market Moving Toward Regenerative Care

The broader biologics market is being shaped by several tailwinds:

• Innovation in bone biologics: New formulations—such as demineralized bone matrices (DBM), bioactive glass, and synthetic scaffolds—are becoming staples in fusion surgeries.

• ASC expansion: As more spine procedures shift to the outpatient setting, surgeons are seeking biologics that are easy to handle, compatible with MIS techniques, and clinically validated.

Spotlight: NanoFUSE Biologics

One example of this evolution is NanoFUSE, a next-generation biologic that combines DBM with bioactive glass—the first of its kind to receive FDA clearance in the U.S. This dual-action formulation is designed to stimulate bone growth while fitting seamlessly into both pain and spine workflows.

NanoFUSE reflects a broader market trend: biologics are no longer just passive fillers—they’re engineered tools that activate biological healing.

Looking Ahead: Biologics as a Standard, Not a Supplement

With biologic-enhanced procedures rising in volume and complexity, it's expected that biologics will play a central role in 80–90% of fusion surgeries by the early 2030s. Companies and physicians that align with this regenerative shift will lead the charge in improving outcomes, optimizing costs, and expanding patient access.

Whether you're a provider, ASC operator, or investor, understanding where biologics are headed isn't just helpful. It’s essential.